This website uses cookies to ensure you get the best experience on our website. Learn more
A global problem
Every year, over 5 million people are diagnosed with cancer in their
digestive system.
The Data-Driven Diagnostics Company
Our unique approach combines expertise in gastrointestinal oncology, digital pathology and AI-driven biomarker discovery.
Rising incidence
One of the deadliest cancers occurs in the esophagus, with cases growing at an alarming rate.
Symptoms like heartburn can cause Barrett’s Esophagus, a precursor to cancer.
9 out of every 10 affected patients are undiagnosed.
Symptoms like heartburn can cause Barrett’s Esophagus, a precursor to cancer.
9 out of every 10 affected patients are undiagnosed.
Poor survival
Some patients with Barrett’s will develop advanced esophageal cancer and have a devastating five-year survival rate of less than 15%.
Diagnostics are the bottleneck
It is impossible to perform an invasive endoscopy on every patient at risk of esophageal cancer.
This needs to change
- 2023
- 2024
- 2025
- 2026
- 2027
Diagnosing cancer
earlier and faster
Our technologies give doctors access to less invasive and better diagnostics for diseases such as Barrett’s esophagus, so we can reduce deaths from late-stage cancer.
Work with the emerging leader in digital diagnostics and transform healthcare
What we do
EndoSign®
Detecting Esophageal cancer early
EndoSign® is a fast and simple test to protect esophageal health by detecting and monitoring for signs of pre-cancer and other diseases.
Cyted Laboratories
Improving patient care
We provide histopathology as a service to public as well as private healthcare providers. Through our unique clinical pathway and data platform, we are positioned to change patient journeys by leveraging pathology data at scale.
Cyted CEO Marcel Gehrung gives evidence to House of Commons Health and Social Care Committee's Future Cancer inquiry
31 Jul 2023
Heartburn Health Check rolled out to NHS patients as test cuts waiting times and helps prevent cancer
16 Jun 2023
